This review highlights the convergence of nanoparticles (NPs) and artificial intelligence (AI) for targeted drug delivery in cancer therapy. It discusses the advantages and challenges of using NPs for drug delivery, focusing on overcoming limitations of conventional chemotherapy like poor bioavailability and non-specific targeting. The review emphasizes the role of AI in addressing these challenges, including biomarker detection, prediction of NP-drug interactions, and optimization of drug efficacy. While acknowledging the limited research specifically on this convergence, the study aims to showcase recent advances and future potential in personalized cancer treatment.
